Liposomes are a useful means of delivering molecular targeting agents such as small interfering RNA (siRNA) to downregulate specific pathways important in cancer growth and progression. The ability to non-invasively image these carriers is important to ascertain their delivery within the tumor. As cyclooxygenase-2 (COX-2) is an important therapeutic target in cancer, we investigated loading COX-2-specific siRNA into cationic liposomes containing MR contrast agents for imaging delivery in cancer cells and tumors. COX-2 and GAPDH siRNA, as well as Magnevist or Feridex, were loaded directly into the liposomes. These lipoplexes were used for cell transfection of the poorly differentiated and highly metastatic breast cancer cell line MDA-MB-231. PEGylated liposomes loaded with Feridex and fluorescently labeled COX-2 siRNA were used for in vivo delivery of lipoplexes in MDA-MB-231 breast cancer xenografts in female SCID mice. Transient transfection assays demonstrated potent and specific downregulation of the COX-2 protein in cells in culture. Tail vein injections of PEGylated COX-2 lipoplexes resulted in intratumoral delivery of siRNA. Biodistribution studies showed significant localization in the lung, liver and kidney at 24 h. These data demonstrate the feasibility of liposomal-mediated delivery of COX-2-specific siRNA to downregulate COX-2 in cancer cells, and multi-modality imaging of the delivery of specific siRNA in tumors.
Introduction
The cyclooxygenase (COX) pathway is the target of several clinical trials for diseases with high inflammatory components such as cancer. COX-2 is a cytoplasmic enzyme responsible for the conversion of arachidonic acid to active lipid mediators, the expression of which is induced by pro-inflammatory cytokines such as IL-1b. COX-2 is upregulated in different cancers such as colon, 1 prostate 2 and breast. 3 We have demonstrated earlier that silencing COX-2 using a COX-2-specific short hairpin RNA molecule stably expressed in the poorly differentiated and highly metastatic breast cancer cell line MDA-MB-231 delayed tumor formation and inhibited extrapulmonary metastasis in an experimental model of metastasis. 4 The ability to effectively deliver COX-2 siRNA to tumors would provide a means to downregulate the COX-2 pathway as a novel therapeutic option.
Several vehicles for systemic delivery of small interfering RNA (siRNA) delivery such as cationic liposomes are currently being evaluated. Cationic liposomes have been used earlier as an alternative to viral delivery of nucleic acids, particularly for anticancer therapy. [5] [6] [7] [8] Successful gene silencing has been achieved using commercially available liposome-based transfection reagents such as lipofectamine, oligofectamine or synthetically prepared liposomes 9, 10 in cultured cells. Although the efficient delivery of siRNA-liposome complexes (lipoplexes) in vivo is limited by factors such as toxicity, enzymatic degradation, target specificity and poor vascular delivery, 11 several studies have described successful downregulation of target molecules using liposome-mediated delivery. The advantage of using liposomes as compared to other delivery systems is that they consist of sealed bilayer membranes made of largely naturally occurring lipids that are similar to biological membranes. Liposomes can fuse with cell membranes 12 so that the aqueous compartment becomes contiguous with the cytosol of the cell, delivering encapsulated material. DOTAP (1,2-dioleoyl-3-trimethylammonium-propane) liposomes have been used earlier to systemically deliver siRNA directed against TNF-a; 13 intraperitoneal injections of anti-TNF-a siRNA inhibited lipopolysaccharide-induced TNF-a gene expression.
3-phosphoethanolamine) liposomes decorated with antitransferrin receptor single-chain antibody fragment were used for targeted delivery of siRNA to primary (PC-3/ Capan-1) and metastatic (MDA435/LCC6) tumor models. 15 Improved transfection efficiency was achieved using a pH-sensitive histidine-lysine peptide complexed to the liposomes for delivery of a modified HER-2-specific siRNA molecule. 16 Chemically modified 'siHybrid' molecules have also been used against MDA-MB-435 human cancer xenografts in mice and showed greater inhibition of HER-2 expression and induction of apoptosis as compared to unmodified siRNA. 17 Delivery of galactosylated lipoplexes to liver parenchymal cells resulted in 80% inhibition of the endogenous Ubc13 gene expression. 18 LIC-101 cationic liposomes were used to deliver bcl-2-specific siRNA to tumor cells in the mouse liver and showed inhibition of tumor cell growth in a prostate cancer model after intravenous administration of the complex. 19 Although several studies have demonstrated the efficient delivery of siRNA in vivo using fluorescence 16, 18, 19 and bioluminescence imaging, 20 relatively few studies have used non-invasive magnetic resonance imaging (MRI) to monitor siRNA delivery. 21 In this study, we investigated the possibility of directly loading COX-2-specific siRNA into DOTAP/DOPE and DOTAP/DOPE/DOPE-PEG2000 (PEG2000: polyethylene glycol, MW 2000 Da) cationic liposomes. Multifunctional liposomes were prepared by lipid hydration and loaded with fluorescently labeled siRNA during the hydration step. We tested iron (Fe)-and gadolinium (Gd)-based contrast agents incorporated into the liposomes for MRI detection of delivery, and observed that iron, but not Gd-based contrast agents, could be incorporated to lipoplexes without loss of COX-2 siRNA-mediated target specificity. To prevent recognition by macrophages and prolong circulation of lipoplexes in vivo, cationic liposomes were decorated with PEG. Our results demonstrate successful intratumoral delivery as detected by imaging of DY647-labeled COX-2-specific siRNA (optical imaging) delivered by PEGylated and Feridex-loaded lipoplexes (MRI) in the MDA-MB-231 human breast cancer xenograft model.
Materials and methods
Cell culture MDA-MB-231 cells were originally derived from the pleural effusion of a breast cancer patient 22 and grown as a monolayer in RPMI 1640 (Sigma-Aldrich, St Louis, MO) medium supplemented with 8.25% fetal bovine serum (FBS). Cells were incubated at 37 1C in a humidified incubator with 5% of CO 2 . Medium was changed every 2-3 days.
Cationic lipids and contrast agents
Cationic lipids DOTAP, DOPE, DOPE-PEG2000 and DOPE-RhodB were purchased from Avanti Polar Lipids (Alabaster, AL Preparation, loading with siRNA and characterization of liposomes For cell studies, cationic liposomes DOTAP/DOPE (3:1 molar ratio) abbreviated as DD and DOTAP/DOPE/ DOPE-PEG2000 (3:0.95:0.05 molar ratio) abbreviated as DDP were prepared using the lipid hydration method. Briefly, lipids (total 3 mmol, 1 mg ml À1 of total lipids) were dissolved in chloroform and a small amount (0.2 mol %) of DOPE-rhodamine B was added to confirm internalization and localization in cells using fluorescence microscopy. The solvent was removed by evaporation using argon flow and residual chloroform was removed overnight using a rotary evaporator. siRNA against COX-2 and GAPDH were prepared from a stock solution (100 mM) in reduced-serum medium (OPTIMEM; Invitrogen). The lipid film was then hydrated with OPTIMEM containing siRNA molecules such that the final liposome concentration for cell transfections was approximately 40 mg ml À1 and the final concentration of siRNA was approximately 40 nM. After hydration for 10-15 min, the suspension was slowly vortexed and complexes allowed to form for an additional 20 min. The DD and DDP liposomes were also loaded with three different contrast agents, Gd-BOA (DDGd and DDPGd), or Magnevist (DDM and Gd-DTPA, 5 mM) or Feridex (DDFe and DDPFe 110 mg ml À1 ). Gd-BOA was incorporated within lipid bilayers in place of 50 mol % of the DOTAP during the formation of liposomes, so that the final concentration of contrast agent was 37.5 mol % in the final liposome formulation. Magnevist or Feridex were added during the hydration step without changes in the lipid ratio.
The excess of Magnevist was removed using a Millipore microcon filter spin column (YM 100; Millipore Corporation, Bedford, MA). The charge ratio of nucleic acid backbone phosphates to cationic lipid/Magnevist was 0.1:0.004:1.
To analyze the incorporation of Feridex in the liposomes, we purified DDPFe lipoplex using sizeexclusion chromatography with Sepharose CL-2B beads (Sigma-Aldrich). Several fractions were collected and Additionally, we separated unincorporated DY-647-labeled siRNA using a Microcon YM-100 size-exclusion spin column. No fluorescence was detected in the eluate using a UV-VIS spectrophotometer (Beckman Coulter, DU, Fullerton, CA). In contrast, significant fluorescence was detected in the lipoplexes retained in the excluded top part of the column following centrifugation at 500 g for 12 min (data not shown). We therefore concluded that most of the siRNAs was incorporated into the liposomes. DY-647-labeled siRNA was used to avoid the background absorbance observed due to the presence of liposomes between 230 and 550 nm. Using a similar method, we estimated that the loss of the siRNA during the extrusion step is about 5%.
The concentration of Gd 3 þ and iron ions in the final lipolex suspensions were determined by inductively coupled plasma mass spectrometry (ICP-MS) (Perkin Elmer/Sciex Elan DRC II, Concord, ON, Canada).
T 1 and T 2 relaxation times were measured at a 9.4 T MR Spectrometer (Bruker BioSpin GmBH, BioSpec, Rheinstetten, Germany). T 1 relaxation times of DDGd, DDPGd and DDM lipoplexes were measured with a saturation recovery sequence. In these experiments, the repetition time (TR) was 8 s, the echo time (TE) was 1.142 ms, the field of view was 3.2 cm, matrix size was 128 Â 64, the number of averages (NA) was 4 and the slice thickness was 1 mm. The saturation recovery times were 10, 20, 50, 100, 200, 400, 800, 1000, 2000 and 4000 ms.
The T 2 relaxation times of DDFe and DDPFe lipoplexes were measured with a T 2 -weighted MSME sequence. Acquisitions with a TR of 500 ms, and TE of 8, 16, 24, 32, 40 and 48 ms, number of averages of 4, 1 slice and slice thickness of 1 mm were used. The images were reconstructed using custom-written software in the Interactive Data Language (IDL) programming environment. The final analysis of T 1 and T 2 values was performed with ImageJ (National Institute of Health, Bethesda, MD) (Supplementary Table 1 ).
For in vivo experiments, 200 ml of DDP liposome/ siRNA complex (10 mg ml À1 and 150 ml of 100 mM) with a calculated charge ratio of nucleic acid backbone phosphates to cationic lipid 1:3 was passed through a 100 nm pore size polycarbonate membrane using a sterile extruder (Avestin Inc., Canada), washed earlier with nuclease-free sterile water to prevent degradation of siRNA during the extrusion step.
The hydrodynamic diameters of lipoplexes used for the in vivo experiments were measured in OPTIMEM and their z potential in 10 mM of NaCl at 25 1C in two independent experiments using a Malvern Zetasizer (Malvern Instruments Inc., Southborough, MA). Each measurement was repeated at least three times.
MTT cell viability assay MDA-MB-231 cells (2 Â 10 3 ) were seeded in 96-well plates and allowed to recover from trypsinization for 24 h. Liposomes alone and COX-2 and GAPDH lipoplexes were added and plates were returned to a tissue culture incubator for 4 h. The medium was then replaced with RPMI 1640 supplemented with 8.25% FBS without phenol red and cells were cultured for an additional 20 h. After incubation, 10 ml of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) dye solution (ATCC Bioproducts, Manassas, VA) was added into each well and cells were incubated for an additional 4 h. In total, 100 ml of detergent reagent was then added to each well and plates were incubated overnight in the dark at room temperature. 
Western blot analyses
To determine COX-2 and GAPDH protein expression levels, MDA-MB-231 cells (1.7 Â 10 6 ) were seeded in 100 mm Petri dishes and transfected with lipoplexes for 24 h. Cells were washed once with 1 Â PBS, harvested, centrifuged and resuspended in mammalian protein extraction reagent, M-PER (Pierce, Rockford, IL) solution with protease inhibitor cocktail (1:750; SigmaAldrich). The total protein amount was determined using the D C protein assay (Bio-Rad, Hercules, CA). Immunoblotting was performed following standard protocols. The Immobilon transfer membrane (Millipore Corporation) was incubated overnight at 4 1C with COX-2 polyclonal antibody (1:1000; Cayman Chemical, Ann Arbor, MI) or for 1 h with GAPDH polyclonal antibody (Santa Cruz Biotechnology, Santa Cruz, CA) or actin monoclonal antibody (1:50 000; Jackson Immunoresearch Laboratories Inc., West Grove, PA) in 5% skimmed milk. Horseradish peroxidase-conjugated secondary anti-rabbit, anti-goat and anti-mouse antibodies (1:2000; Jackson Immunoresearch Laboratories Inc.) were added and proteins were visualized using WestPico Chemiluminescence detection reagent (Pierce). International, Rochester, NY). Cells were transfected as described above using a scaled down amount of lipoplexes. After 24 h, cells were washed three times with 1 Â PBS, fixed with 3% of paraformaldehyde and imaged using a Nikon ECLIPSE-TS100 fluorescence microscope (Nikon Instrument Inc., Melville, NY). Images were digitized using a Nikon Coolpix 5000 digital camera (Nikon Corporation, Tokyo, Japan).
Optical imaging
In vivo delivery and imaging All in vivo studies were performed in compliance with institutional guidelines established by the Institutional Animal Care and Use Committee of Johns Hopkins University. A total of 14, 5-to 6-week old female SCID mice were inoculated subcutaneously in the mammary fat pad with 2 Â 10 6 MDA-MB-231 cells suspended in 50 ml of Hanks balanced salt solution. When tumor sizes reached B200 mm 3 , 250-280 ml of DDP-DY647-labeled COX-2 lipoplexes were injected intravenously (i.v.) and mice were imaged with a Xenogen IVIS 200 optical imaging device (data not shown). DY647-labeled COX-2 siRNA without liposomes were also injected i.v. and used as a control. Animals were killed at 0.5, 3, 8 and 24 h time points and tumor, liver, kidney, spleen, lungs and stomach were imaged as separate organs. For biodistribution studies, mice (n ¼ 3) were injected with lipoplexes for 24 h and 1-mm-thick slices of organs and tumor were imaged using the Xenogen IVIS system. Instrument settings were normalized to identical exposures for image processing and quantification. For fluorescence studies, organs and tumors were frozen in liquid N 2 , embedded in OCT (Optimal Cutting Temperature) compound medium for frozen tissue specimens; (Sakura Finetek, USA Inc., Torrance, CA, USA), and stored at À80 1C until further use. Each organ was cut in 10-mm-thick sections, fixed with 3% of paraformaldehyde and examined by fluorescence microscopy using a Nikon ECLIPSE-TS100 microscope (Nikon Instrument Inc.). Nuclei were stained with DAPI (4,6-diamidino-2-phenylindole) (ProLong Gold antifade reagent; Invitrogen, Molecular Probes, Eugene, OR).
Additionally, DDP-COX-2 lipoplexes were loaded with Feridex to monitor the delivery of siRNA using MRI. In this set of experiments, a total of five tumor-bearing female SCID mice were injected i.v. with DDPFe-COX-2 lipoplexes. Tumors were imaged at 3 and 24 h postinjection on a Bruker 9.4 T horizontal bore (Bruker BioSpin GmBH, Rheinstetten, Germany) spectrometer using a T 2 -weighted 3D RARE (rapid acquisition with rapid enhancement, TR ¼ 500 ms, TE ¼ 30, 50 and 100 ms, field of view 16 Â 16 Â 8, matrix size 128 Â 64 Â 32, zerofilled to 128 Â 128 Â 64, NOA ¼ 2) sequence. The resulting spatial resolution was 0.125 mm Â 0.125 mm Â 0.125 mm. Images were processed using custom tools developed in IDL (ITT Visual Information Solutions, Boulder, CO). T 2 -weighted 3D RARE images (TE ¼ 50 ms) at 0, 3 and 24 h were aligned by affine registration using Amira (Visage Imaging, Carlsbad, CA). Subsequently, histogram intensities of each image at 3 and 24 h post-injection were normalized to the histogram intensities from pre-contrast images. Representative slices of the tumor at each time point were identified, and the histograms for a region of interest computed using ImageJ. T 2 -weighted 3D RARE images (TE ¼ 30, 50 and 100 ms) were also processed using IDL to obtain quantitative T 2 maps. T 2 maps at 0, 3 and 24 h post-injection were co-registered and analyzed in the same manner as described above. After MRI experiment, animals were killed and the tumors were frozen in OCT for immunohistochemistry. To confirm the presence of Feridex within tumors, 10-mm frozen sections were stained with anti-dextran FITC antibody (StemCell Technologies Inc., Vancouver, BC, Canada) and nuclei were stained with DAPI. Images were taken using a Nikon ECLIPSE-TS100 microscope.
Liver toxicity test Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were purchased from Pointe Scientific Inc. (Canton, MI). Levels of ALT and AST in the serum were checked at 24 h post-intravenous injection from mice injected with DDPFe-COX-2 lipoplexes (n ¼ 3) and from uninjected mice (n ¼ 3).
Statistical analysis MRI data were analyzed and presented as mean ± s.e.m. P-values were determined by an unpaired Student's t-test. Po0.05 was considered significant.
Results

Lipoplex preparation and characterization
Cationic liposomes DD, DDFe, DDGd, DDM, DDP, DDPFe and DDPGd were prepared by lipid hydration from the corresponding lipids. The contrast agents Magnevist or Feridex were loaded directly during lipid hydration with OPTIMEM and Gd-BOA was incorporated within lipid bilayers during the formation of DDGd and DDPGd liposomes. For in vivo experiments, lipoplexes were extruded using a 100 nm polycarbonate membrane. Physical characteristics of extruded lipoplexes are shown in Table 1 . The hydrodynamic diameter of COX-2-bearing lipoplexes was in the range of 260-310 nm. The presence of PEG on the surface of liposomes resulted in steric stabilization of lipoplexes except for Abbreviation: COX-2, cyclooxygenase-2.
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PEGylated lipoplexes have low toxicity in cells
The toxicity of liposomes and lipoplexes was assessed using the MTT cell viability assay (Figure 2b Because we observed nonspecific downregulation of COX-2 siRNA in cells using DDGd, DDPGd and DDM lipoplexes in the presence of Gd 3 þ ions, but more specific downregulation of COX-2 in the presence of Fe (Feridex), using DDFe liposomes, we next examined the delivery of COX-2 siRNA using PEGylated DD liposomes loaded with Feridex. Representative T 2 -weighted images of a tumor are shown in Figure 5a . These T 2 -weighted images revealed changes in the contrast enhancement at 3 h as compared to the pre-contrast images. The decrease of signal intensity became even more prominent at 24 h (Supplementary Figures 1-3) . On the histograms computed from T 2 maps (Figure 5b) , a shift to lower T 2 values at 3 and 24 h is clearly seen, which indicates the presence of DDPFe-COX lipoplexes in the tumor. These data are in good agreement with data obtained with optical imaging. Analysis of the intensity of T 2 maps, quantified using ImageJ, is shown in Figure 5c . These data demonstrate that at 3 and 24 h post-injection of lipoplexes there is a significant reduction of T 2 values (n ¼ 5, *Po0.004 and **P ¼ 0.02). High fraction of undecorated DDP-COX-2 lipoplexes are localized primarily in the lungs To investigate the localization of DDP-COX-2 lipoplexes, 10-mm sections of lungs, liver and kidney were obtained and analyzed by fluorescence microscopy. A strong fluorescent signal from COX-2 siRNA was observed in the lung and liver of injected animals as early as 0.5 h post-injection and this signal remains high at 3 h. In contrast, the fluorescent intensity in the kidney was lower at 0.5 h than at 3 h postinjection (Figures 6a and b) . The localization of COX-2 siRNA at 8 h was more pronounced in the lungs and kidneys, whereas the fluorescent intensity in liver diminished (Figure 6c) . At 24 h post-injection, the overall amount of fluorescence was reduced (Figure 6d) .
To quantify the biodistribution of fluorescent signal from DY647-labeled COX-2 siRNA lipoplexes, the fluorescence intensity of 1 mm organ and tumor sections obtained 24 h post-injection was digitized and measured using a Xenogen IVIS 200 (Figure 7) . The highest fluorescence intensity was observed in lungs, kidney, stomach and liver. Tumor and spleen fluorescence was also detected, whereas no fluorescence could be detected in the heart or muscle.
To evaluate the effect of DDPFe-COX-2 lipoplexes on liver toxicity, we monitored the levels of AST and ALT in the serum from treated and control mice as elevated levels of AST and ALT reflect liver toxicity. 24 In this assay, DDPFe-COX-2 lipoplexes were injected every 24 h for 4 days and serum was collected on the fifth day, at 96 h post-injection. No significant differences were observed in AST (P ¼ 0.99) and ALT (P ¼ 0.61) levels between treated and control mice (Supplementary Figure 3) .
Discussion
Inflammation is currently considered a major contributor to tumor progression and metastasis.
1-4 COX-2 function Delivery and imaging of COX-2 siRNA M Mikhaylova et al is targeted in many active clinical trials using COX-2-selective pharmacological inhibitors. The COX-2-independent functions of these inhibitors 25 have increased the demand for more potent and specific COX-2 inhibitors. Using a COX-2-specific shRNA, we demonstrated earlier that poorly differentiated metastatic breast cancer cells are dependent on the expression of COX-2 for tumor onset and extrapulmonary metastasis, 4 making COX-2 an attractive target in cancer. Here, we have characterized the efficacy of COX-2 downregulation in cells and detected the in vivo delivery of cationic liposomes directly loaded with COX-2 siRNA using optical and MR imaging.
Efficient non-viral delivery of siRNA requires stable formulation and targeting of lipoplexes to the growing tumors as well as specificity and functionality of the delivered siRNA cargo. Several recent reports have demonstrated the efficacy of DOTAP/DOPE cationic liposomes in delivering antisense oligonucleotides and siRNA to targeted tumors. 7, 15, 17 In our study, lipoplexes were formed by mixing positively charged cationic liposomes with negatively charged siRNA in reduced serum medium. PEG was included in the lipoplex formulation to increase their circulation time following i.v. injection and to reduce the toxicity of the lipoplexes. The presence of PEG may affect the capacity of liposomes to carry siRNA molecules or decrease the efficiency of intracellular delivery. We therefore sought to improve the transfection efficiency of liposomes by mixing COX-2 siRNA with DDP lipids during the hydration step before the liposomes formed using pre-made PEGylated lipids. Earlier, PEGylated liposomes used to deliver antisense oligonucleotides or siRNA have been formed by attaching PEG moieties after the formation of the lipoplexes. 26 Santel et al. 27 recently demonstrated downregulation of Tie2 and CD31 in the mouse vascular endothelium using PEGylated cationic lipoplexes and targeted siRNA. The presence of PEG was observed to reduce toxicity in vivo as compared to nonPEGylated lipoplexes. 27 Lipoplexes were prepared by mixing pre-made PEGylated liposomes with siRNA such that the concentration of PEGylated lipids was 1%. An increase in the amount of PEG up to 5% resulted in the complete abolishment of gene silencing. In our study, we used 1.25 mol % of PEGylated lipids in the DDP formulation for cell and in vivo studies, and also observed that this concentration of PEG did not alter the specific downregulation of COX-2. We found that siRNA molecules delivered by DD or DDP cationic liposomes specifically silenced COX-2 expression in cells. Our results also show that direct loading of siRNA did not influence PEGylation of DD liposomes reversed the moderate toxicity of DD-COX-2 lipoplexes on cell viability with little, if any, effect on the potency and no effect on the specificity of the lipoplexes. These data are in agreement with previous data 15, 28 where no cytotoxic effect was observed with DOTAP/DOPE liposomes.
To investigate the effects of the incorporation of ironbased contrast agents, we loaded DD liposomes with Feridex and corresponding siRNA complexes. Our results showed that Feridex incorporation into DD-COX-2 lipoplexes did not significantly affect their specificity. These data are consistent with the current use of Feridex as an intracellular contrast agent for cell tracking by MRI. 29 To optically image the localization of DDP-delivered COX-2 siRNA in vivo, a DY647 moiety was covalently linked to the siRNA. Fluorescence was detected in tumor sections as early as 0.5 h after i.v. injection. The intracellular localization of DY647-labeled siRNA was observed, although more diffused, in the tumor tissue even 24 h post-injection despite the absence of specific tumor targeting moieties. The delivery of siRNA to the tumor cells through the leaky tumor vasculature is consistent with the enhanced permeability and retention effect observed with non-targeted liposome delivery. 30 Our data show that siRNA was delivered to the tumor most likely through the liposomes, and that the fluorescent signal at a later time point may arise from DY647-labeled DDP-COX-2 lipoplexes in the circulation. It is also possible that following COX-2 siRNA binding to endogenous COX-2 mRNA and its degradation by the RISC complex, free DY647 may have remained inside tumor cells.
The results of fluorescence microscopy of different organs indicate that a high fraction of DY647-labeled DDPFe-COX-2 siRNA lipoplex was found in the lungs, liver and spleen at earlier time points. These data are in agreement with previously published data on biodistribution of cationic liposome/oligonucleotide complex following intravenous injection. 31 In that study, the authors observed accumulation of cationic liposomes primarily in the liver and spleen and cationic liposomes/oligonucleotide complex in lungs at 15 min post i.v. injection that gradually redistributed to the liver by 24 h. In a different study, the influence of different serum components such as bovine serum albumin, lipoproteins (high-density lipoprotein and low-density lipoprotein) and macroglobulin on the delivery of cationic lipid/oligonucleotide complexes in vivo and in vitro was studied. 32 It was shown that oleic acid and heparin, found in the serum, would most likely affect the delivery in vivo and in vitro by displacing the oligonucleotide from the lipid complex. It was therefore suggested that incorporation of helper lipids such as cholesterol or DOPE would result in the delivery of the complex in the presence of serum in the medium. In the current study, we used DOPE as a helper lipid to reduce the interaction of the complex with serum in plasma.
We also demonstrated the ability to image the intratumoral delivery of COX-2 lipoplexes in vivo using MRI. DDPFe-COX-2 siRNA lipoplexes were detected in the tumor at 3 and 24 h post-injection using MR, and the presence of Feridex was confirmed by immunohistochemistry. AST and ALT levels in the serum of mice injected with DDPFe-COX-2 complex were comparable to values obtained from uninjected control mice, indicating that the DDPFe-COX-2 lipoplexes did not induce liver toxicity.
Our findings demonstrate that metastatic MDA-MB-231 breast cancer cells can be efficiently transfected using COX-2 siRNA complexed with DD or DDP liposomes. COX-2 siRNA can be directly loaded into cationic DD and DDP liposomes without changing the siRNA functionality. The incorporation of MR contrast agents within liposomes creates the possibility of imaging siRNA delivery in vivo with MRI with a clear path of clinical translatability. In the future, MRI can be used to understand the effect of COX-2 siRNA delivery and downregulation on vascular and metabolic function.
